SLU-PP-332oral SLU-PP-332 is a synthetic compound that has garnered significant attention in research circles for its potential to mimic the metabolic effects of exercise. As a potent and selective estrogen-related receptor (ERR) agonist, SLU-PP-332 primarily targets ERRα, demonstrating promising preclinical efficacy in alleviating conditions associated with metabolic syndrome. Research indicates that this compound can influence fat metabolism, enhance mitochondrial function, and increase energy expenditure, positioning it as a key area of study for metabolic and endocrinology researchExercise-mimicking drug sheds weight, boosts muscle activity ....
The primary mechanism by which SLU-PP-332 operates is through its interaction with estrogen-related receptors (ERRs). Specifically, it acts as a pan-agonist, meaning it activates ERRα, ERRβ, and ERRγ, with the strongest affinity for ERRα. These receptors play a crucial role in regulating energy metabolism, mitochondrial biogenesis, and muscle function. By activating these receptors, SLU-PP-332 can effectively stimulate pathways that are typically engaged during physical activityDiscover the Benefits and Risks of SLU PP 332. This activation leads to increased fatty acid oxidation, enhanced glucose tolerance, and a reduction in fat mass accumulation, as observed in various animal studies. The compound's ability to promote these exercise-like effects at a cellular level makes it a compelling subject for scientific investigation.
Preclinical research, primarily conducted in animal models, has yielded encouraging results regarding the potential applications of SLU-PP-332. Studies have shown that administration of SLU-PP-332 can lead to significant reductions in body weight and fat mass in obese mice, alongside improvements in glucose metabolism2023年9月27日—A brand-new kind of drug, tested in mice, shows promising new results that could lead to the development of a new weight-loss drug that mimics exercise.. These findings suggest a potential role for ERR agonists like SLU-PP-332 in the treatment of metabolic disorders such as obesity and type 2 diabetes.A Synthetic ERR Agonist Alleviates Metabolic Syndrome - PMC Furthermore, its capacity to boost muscle activity and endurance has led to its characterization as an "exercise in a pill," offering a novel therapeutic avenue for individuals who may not be able to engage in strenuous physical activity. The research also highlights its potential in enhancing mitochondrial health and cellular energy production, further underscoring its broad impact on metabolic regulationSLU-PP-332 (8112) by Tocris, Part of Bio-Techne.
It is crucial to emphasize that SLU-PP-332 is currently designated as a research-only compound. It has not received FDA approval for human use, and its medical applications are still under investigation. The substance is available from various research chemical suppliers, often marketed as a high-purity research peptide for laboratory use only. These suppliers typically provide detailed specifications, including purity levels (often exceeding 99%), and available quantities ranging from micrograms to grams.Exercise-mimicking drug sheds weight, boosts muscle activity ... Researchers utilize SLU-PP-332 in laboratory settings to explore its effects on metabolic pathways, cellular energy, and potential therapeutic benefits, contributing to the growing body of scientific knowledge surrounding this compound.
The ongoing research into SLU-PP-332 holds significant promise for advancing our understanding of metabolic regulation and developing novel therapeutic strategies.2024年10月21日—structure, and solubility data support its potential as a small molecule drug in endocrinology and metabolic diseases. Furtherresearchis ... As studies progress, further investigation into its long-term effects, optimal dosing protocols, and potential side effects will be essentialSLU-PP-332isa potent and selective pan estrogen related receptor (ERR) agonist(EC 50 values are 98 nM, 230 nM and 430 nM for ERRα, ERRβ and ERRγ respectively. While the current research focuses on its potential benefits, it is imperative for researchers and institutions to adhere to strict laboratory safety guidelines and ethical considerations when handling and experimenting with this potent research chemicalSLU-PP-332is a compound which is a potent but non-selective estrogen-related receptor (ERR) agonist, acting most strongly at ERRα with an EC50 of 98 nM.. The development of SLU-PP-332 as a potential therapeutic agent underscores the exciting advancements in peptide research and its capacity to unlock new possibilities for addressing complex health challenges.
Join the newsletter to receive news, updates, new products and freebies in your inbox.